Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MDM4 | O15151 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.48 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7822425 | 1.00 | CASP3 (0.54) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL31610887 | 1.00 | CASP3 (0.54) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL29908073 | 1.00 | CASP3 (0.54) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL1486191 | 1.00 | CASP3 (0.54) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL119400 | 1.00 | CASP3 (0.54) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL1486209 | 1.00 | CASP3 (0.54) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL29477078 | 1.00 | CASP3 (0.54) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL30147576 | 1.00 | CASP3 (0.54) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL2551441 | 1.00 | CASP3 (0.54) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL27843401 | 1.00 | CASP3 (0.54) | CASP3KMT2AMDM4TP53EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 518 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116848-A1 | Synthesis of an Intermediate and Its Use for the Preparation of GLP-1R/GIPR Agonists | CARMOT THERAPEUTICS INC. (US) | 2026-04-30 | — | — | US | claimed |
| CN-119978062-A | Synthesis method of anti-freeze glycopeptide polypeptide | 安徽省国平药业有限公司 | 2025-05-13 | — | — | CN | claimed |
| CN-119874813-A | Short peptide compound and preparation method thereof, cosmetic composition and application | 常州市智态生创科技有限公司 | 2025-04-25 | — | — | CN | claimed |
| CN-119591674-A | Cyclohexapeptide and preparation method and application thereof | 陕西未来多肽生物科技有限公司 | 2025-03-11 | — | — | CN | claimed |
| CN-119529056-A | Solid phase preparation method of telipopeptide | 福建基诺厚普生物科技有限公司 | 2025-02-28 | — | — | CN | claimed |
| CN-119371515-A | Synthesis method of salmon calcitonin acetylation impurity | 翰宇药业（武汉）有限公司 | 2025-01-28 | — | — | CN | claimed |
| CN-119241653-A | Lutetium (lutetium)177Preparation method of Lu-oxyoctreotide precursor compound | 迈得诺医疗科技集团有限公司 | 2025-01-03 | — | — | CN | claimed |
| CN-119039972-A | Preparation method and application of multi-target enzymatic self-assembled fluorescence activation type nano probe | 徐州医科大学 | 2024-11-29 | — | — | CN | claimed |
| CN-118005766-B | Solid phase synthesis method of Glepaglutide | 杭州信海医药科技有限公司 | 2024-09-27 | — | — | CN | claimed |
| CN-111944039-B | Synthetic method of somalupeptide | 深圳市健元医药科技有限公司 | 2024-09-06 | — | — | CN | claimed |
| CN-114774395-A | High-purity chitinase 3-like protein 1 epitope peptide for liver disease detection and preparation method thereof | 亿彤科技发展(福建)有限公司 | 2022-07-22 | — | — | CN | claimed |
| WO-2022141615-A1 | SYNTHESIS METHOD FOR ATOSIBAN | 湖北健翔生物制药有限公司 | 2022-07-07 | — | — | WO | claimed |
| CN-114685614-A | Solid-phase synthesis method of atosiban | 湖北健翔生物制药有限公司 | 2022-07-01 | — | — | CN | claimed |
| CN-114591391-A | Synthesis process of O-sugar peptide bond polypeptide | 湖北强耀生物科技有限公司 | 2022-06-07 | — | — | CN | claimed |
| CN-114539358-A | Polypeptide, preparation method and application | 中国科学院大连化学物理研究所 | 2022-05-27 | — | — | CN | claimed |
| CN-112390859-B | Self-assembly polypeptide probe for identifying Caspase protein, preparation method and application | 南开大学 | 2022-04-05 | — | — | CN | claimed |
| CN-113121673-B | Method for preparing elcatonin by solid-liquid combination method | 润辉生物技术（威海）有限公司 | 2022-03-29 | — | — | CN | claimed |
| CN-111333697-B | Synthesis method of romidepsin | 深圳翰宇药业股份有限公司 | 2022-03-08 | — | — | CN | claimed |
| CN-114057862-A | Synthetic method of GLP-1(1-37) polypeptide | 安徽省国平药业有限公司 | 2022-02-18 | — | — | CN | claimed |
| CN-109180803-B | Somatostatin and preparation method and pharmaceutical composition thereof | 成都天台山制药有限公司 | 2022-02-08 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116848-A1 | Synthesis of an Intermediate and Its Use for the Preparation of GLP-1R/GIPR Agonists | GLP1R, GIPR, CCKBR | CASP3 3659/4885KMT2A 2588/4885MDM4 4227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.